Published in Genetics and Environmental Business Week, October 28th, 2004
The Palo Alto, California, company said it expects 20% net growth in fourth-quarter orders in North America and a 15% increase in international markets.
Although the company did not say how higher demand for its image-guided radiation therapy products would affect earnings, analysts surveyed by Thomson First Call expect the company to report fourth-quarter earnings of 35 cents a share.
Analysts and investors may get a better sense of Varian's...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Genetics and Environmental Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.